Journal Mobile Options
Table of Contents
Vol. 7, No. 5, 2010
Issue release date: July 2010
Neurodegenerative Dis 2010;7:284–290

Clinical Criteria for the Diagnosis of Parkinson’s Disease

Reichmann H.
Klinik und Poliklinik für Neurologie, Universitätsklinikum Carl Gustav Carus, Dresden, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


The diagnosis of Parkinson’s disease (PD) follows the UK Brain Bank Criteria, which demands bradykinesia and one additional symptom, i.e. rigidity, resting tremor or postural instability. The latter is not a useful sign for the early diagnosis of PD, because it does not appear before Hoehn and Yahr stage 3. Early symptoms of PD which precede the onset of motor symptoms are hyposmia, REM sleep behavioral disorder, constipation, and depression. In addition, an increasing number of patients whose PD is related to a genetic defect are being described. Thus, genetic testing may eventually develop into a tool to identify at-risk patients. The clinical diagnosis of PD can be supported by levodopa or apomorphine tests. Imaging studies such as cranial CT or MRI are helpful to distinguish idiopathic PD from atypical or secondary PD. SPECT and PET methods are valuable to distinguish PD tremor from essential tremor if this is clinically not possible. Using all of these methods, we may soon be able to make a premotor diagnosis of PD, which will raise the question whether early treatment is possible and ethically and clinically advisable.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Alves G, Forsaa EB, Pedersen KF, et al: Epidemiology of Parkinson’s disease. J Neurol 2008;255(suppl 5):18–32.
  2. Hughes AJ, Daniel SE, Kilford L, Lees AJ: Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry 1992;55:181–184.
  3. Dickson DW, Braak H, Duda JE, et al: Neuropathological assessment of Parkinson’s disease: refining the diagnostic criteria. Lancet Neurol 2009;8:1150–1157
  4. Hoehn MM, Yahr MD: Parkinsonism. Onset, progression and mortality. Neurology 1967;17:427–442.
  5. Hallett M: Differential diagnosis of tremor; in Vinken PJ, Bruyn GW, Klawans HL (eds): Handbook of Clinical Neurology: Extrapyramidal Disorders, ed 49. New York, Elsevier Science, 1986, pp 583–595.
  6. Rajput AH, Rozdilsky B, Ang L: Occurrence of resting tremor in Parkinson’s disease. Neurology 1991;41:1298–1299.
  7. Findley LJ, Gresty MA: Tremor. Br J Hosp Med 1981;26:16–32.
  8. Clarimón J, Pagonabarraga J, Paisán-Ruiz C, et al: Tremor dominant parkinsonism: clinical description and LRRK2 mutation screening. Mov Disord 2008;15:518–523.

    External Resources

  9. Antonini A, Vontobel P, Psylla M, et al: Complementary positron emission tomographic studies of the striatal dopaminergic system in Parkinson’s disease. Arch Neurol 1995;52:1183–1190.
  10. Findley LJ, Gresty MA: Tremor and rhythmical involuntary movements in Parkinson’s disease; in Findley LJ, Capildeo R (eds): Movement Disorders: Tremor. London, Macmillan, 1984, pp 295–304.
  11. Marsden CD: Slowness of movement in Parkinson’s disease. Mov Disord 1989;4(suppl 1):S26–S37.
  12. Agid Y: Parkinson’s disease: pathophysiology. Lancet 1991;337:1321–1324.
  13. Mendonca DA: Tasks of attention augment rigidity in mild Parkinson disease. Can J Neurol Sci 2008;35:501–505.
  14. Weiner WJ, Nora LM, Glantz RH: Elderly inpatients: postural reflexes impairment. Neurology 1984;34:945–947.
  15. Marttila RJ, Rinne UK: Disability and progression of Parkinson’s disease. Acta Neurol Scand 1977;56:159–169.
  16. Rajput AH, Rozdilsky B, Rajput A: Accuracy of clinical diagnosis in parkinsonism – a prospective study. Can J Neurol Sci 1991;18:275–278.
  17. Williams DR, Lees AJ: Progressive supranuclear palsy: clinicopathological concepts of diagnostic challenges. Lancet Neurol 2009;8:270–279.
  18. Shulman LM, Taback RL, Bean J, Weiner WJ: Comorbidity of the nonmotor symptoms of Parkinson’s disease. Mov Disord 2001;16:507–510.
  19. Braak H, DelTredici K, Rub U, et al: Staging of brain pathology related to sporadic Parkinson’s disease. Neurobiol Aging 2003;34:197–211.

    External Resources

  20. Jellinger K: Recent developments in the pathology of Parkinson’s disease. J Neural Transm 2002;62(suppl):347–376.
  21. Wakabayashi K, Takahashi H, Takeda S, Ohama E, Ikuta F: Parkinson’s disease: the presence of Lewy bodies in Auerbach’s and Meissner’s plexuses. Acta Neuropathol 1988;76:217–221.
  22. Braak H, de Vos RA, Bohl J, Del Tredici K: Gastric alpha-synuclein immunoreactive inclusions in Meissner’s and Auerbach’s plexuses in cases staged for Parkinson’s disease-related brain pathology. Neurosci Lett 2006;20:67–72.

    External Resources

  23. Müller A, Reichmann H, Livermore A, Hummel T: Olfactory function in idiopathic Parkinson’s disease (IPD): results from cross-sectional studies in IPD patients and long-term follow-up of de novo IPD patients. J Neural Transm 2002;109:805–811.
  24. Doty RL, Deems DA, Stellar S: Olfactory dysfunction in parkinsonism: a general deficit unrelated to neurologic signs, disease stage, or disease duration. Neurology 1988;38:1237–1244.
  25. Haehner A, Boesveldt S, Berendse HW, Reichmann H, et al: Prevalence of smell loss in Parkinson’s disease – a multicenter study. Parkinsonism Relat Disord 2009;15:490–494.
  26. Khan NL, Katzenschlager R, Watt H, et al: Olfaction differentiates parkin disease from early-onset parkinsonism and Parkinson disease. Neurology 2004;62:1224–1226.
  27. Katzenschlager R, Zijlmans J, Evans A, Watt H, Lees AJ: Olfactory function distinguishes vascular parkinsonism from Parkinson’s disease. J Neurol Neurosrug Psychiatry 2004;75:1749–1752.
  28. Doty RL, Singh A, Tetrud J, Langston JW: Lack of major olfactory dysfunction in MPTP-induced parkinsonism. Ann Neurol 1992;32:97–100.
  29. Ponsen MM, Stoffers B, Booji J, et al: Idiopathic hyposmia as a preclinical sign of Parkinson’s disease. Ann Neurol 2004;56:173–181.
  30. Sommer U, Hummel T, Cormann K, et al: Detection of presymptomatic Parkinson’s disease: combining smell tests, transcranial sonography, and SPECT. Mov Disord 2004;19:1196–1202.
  31. Haehner A, Hummel T, Hummel C, et al: Olfactory loss may be a first sign of idiopathic Parkinson’s disease. Mov Disord 2007;22:839–842.
  32. Ross GW, Petrovitch H, Abbott RD, et al: Association of olfactory dysfunction with risk for future Parkinson’s disease. Ann Neurol 2008;63:167–173.
  33. Becker G, Seufert J, Bogdahn U, Reichmann H, Reiners K: Degeneration of substantia nigra in chronic Parkinson’s disease visualized by transcranial color-coded real-time sonography. Neurology 1995;45:182–184.
  34. Herting B, Schulze S, Reichmann H, Haehner A, Hummel T: A longitudinal study of olfactory function in patients with idiopathic Parkinson’s disease. J Neurol 2008;255:367–370.
  35. Iranzo A, Molinuevo JL, Santamaria J, et al: Rapid-eye-movement sleep behaviour disorder as an early marker for a neurodegenerative disorder: a descriptive study. Lancet Neurol 2006;5:572–577.
  36. Stiasny-Kolster K, Doerr Y, Moeller CJ, et al: Combination of ‘idiopathic’ REM sleep behaviour disorder and olfactory dysfunction as possible indicator for alpha-synucleinopathy demonstrated by dopamine transporter FP-CIT-SPECT. Brain 2005;128:126–137.
  37. Ziemssen T, Reichmann H: Non-motor dysfunction in Parkinson’s disease. Parkinsonism Relat Disord 2007;13:323–332.
  38. Abbott RD, Petrovitch H, White LR, et al: Frequency of bowel movements and the future risk of Parkinson’s disease. Neurology 2001;57:456–462.
  39. Comella CL, Nardine TM, Diederich NJ, Stebbins GT: Sleep-related violence, injury, and REM sleep behaviour disorder in Parkinson’s disease. Neurology 1998;51:526–529.
  40. Schenck CH, Brundlie SR, Mahowald WM: Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 1996;46:388–393.
  41. Santamaria J, Tolosa E, Valles A: Parkinson’s disease with depression; a possible subgroup of idiopathic parkinsonism. Neurology 1986;36:1130–1133.
  42. Leentjens AF, van den Akker M, Metsemakers JF, Lousberg R, Verhey FR: Higher incidence of depression preceding the onset of Parkinson’s disease: a register study. Mov Disord 2003;18:414–418.
  43. Reijnders JS, Ehrt U, Weber WE, Aarsland D, Leentjens AF: A systemic review of prevalence studies of depression in Parkinson’s disease. Mov Disord 2008;23:183–189.
  44. Riedel O, Klotsche J, Spottke A, et al: Cognitive impairment in 873 patients with idiopathic Parkinson’s disease. Results from the German Study on Epidemiology of Parkinson’s Disease with Dementia (GEPAD). J Neurol 2008;255:255–264.
  45. Double KL, Rowe DB, Carew-Jones FM, et al: Anti-melanin antibodies are increased in sera in Parkinson’s disease. Exp Neurol 2009;217:297–301.
  46. Müller T, Benz S, Boernke CH, et al: Worsened motor test performance following acute apomorphine injection in previously untreated patients with Parkinson’s disease. J Neural Transm 2004;68(suppl):79–87.
  47. Nadjar A, Gerfen CR, Bezard E: Priming for l-dopa-induced dyskinesia in Parkinson’s disease: a feature inherent to the treatment or the disease? Prog Neurobiol 2009;87:1–9.
  48. Diener CH, et al: Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart, Thieme, 2008.
  49. Double KL, Rowe DB, Carew-Jones FM, et al: Anti-melanin antibodies are increased in sera in Parkinson’s disease. Exp Neurol 2009;217:297–301.
  50. Gerhard A, Pavese N, Hotton G, et al: In vivo imaging of microglial activation with [11C]®-PK11195 PET in idiopathic Parkinson’s disease. Neurobiol Dis 2006;21:404–412.
  51. Parkinson Study Group: Pramipexole vs. levodopa as initial treatment for Parkinson disease: a randomized controlled trial. JAMA 2000;284:1931–1938.
  52. Whone AL, Bailey DL, Remy P, Pavese N, Brooks DJ: A technique for standardized central analysis of 6-(18)F-fluoro-L-DOPA PET data from a multicenter study. J Nucl Med 2004;45:1135–1145.
  53. Braune S, Reinhardt M, Schnitzer R, Riedel A, Lücking CH: Cardiac uptake of [123]MIBG separates Parkinson’s disease from multiple system atrophy. Neurology 1999;53:1020–1025.
  54. Tang CC, Poston KL, Eckert T, et al: Differential diagnosis of parkinsonism: a metabolic imaging study using pattern analysis. Lancet Neurol 2010;9:149–158.
  55. Biskup S, Gerlach M, Kupsch A, Reichmann H, et al: Genes associated with Parkinson syndrome. J Neurol 2008;255(suppl 5):8–17.
  56. Hardy J, Lewis P, Revesz T, Lees A, Paisan-Ruiz C: The genetics of Parkinson’s syndromes: a critical review. Curr Opin Genet Dev 2009;19:254–265.
  57. Vlaar AMM, de Nijs T, van Kroonenburgh M, et al: The predictive value of transcranial duplex sonography for the clinical diagnosis in undiagnosed parkinsonian syndromes: comparison with SPECT scans. BMC Neurology 2008;8:42.
  58. Parkinson Study Group: A controlled trial of rasagiline in early Parkinson disease: the TEMPO study. Arch Neurol 2002;59:1937–1943.
  59. Olanow CW, Rascol O, Hauser R, et al: A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Engl J Med 2009;361:1268–1278.
  60. Grosset D, Taurah L, Burn DJ, et al:A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiatry 2007;78:465–469.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50